Literature DB >> 29732157

A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases.

Masakazu Akitake1, Keijiro Kiyoshima1, Akira Yokomizo2, Kenichiro Shiga2, Hirofumi Koga2, Ario Takeuchi1, Masaki Shiota1, Junichi Inokuchi1, Katsunori Tatsugami1, Akito Yamaguchi2, Masatoshi Eto2.   

Abstract

The aim of the present study was to evaluate the prognostic impact of size and number of tumors in primary low-grade (LG) Ta bladder urothelial carcinoma (UC), and thus allow accurate risk stratification of low-risk non-muscle invasive bladder cancer (NMIBC). This study was a retrospective analysis of 245 patients with primary LG Ta UC of the urinary bladder who were treated with transurethral resection. Differences in intravesical recurrence-free survival (RFS) according to various cutoff values of tumor size and tumor number were calculated using Cox proportional hazards model. Median maximum size of tumor was 1.4 cm, and 153 patients (62.4%) had solitary tumors. Forty-nine patients experienced intravesical recurrence during a median 34 months of follow-up. Patients with solitary tumors had significantly longer RFS times compared with those with ≥8 tumors (P=0.003). Patients with larger tumors had significantly shorter RFS times for each cutoff value (P=0.01 for 1.0 cm, P<0.0001 for 1.5 and 2.0 cm, P=0.006 for 3.0 cm). On multivariate analysis, each cutoff value of tumor size was found to be a predictor of RFS; among them, the cutoff of 1.5 cm showed the strongest association (hazard ratio, 4.12; 95% confidence interval, 2.11-8.81; P<0.001). If we consider only lower risk NMIBC patients, such as primary LG Ta, the appropriate cutoff value of tumor size to predict intravesical recurrence might be 1.5 cm, but not 3.0 cm generally adopted in various guidelines. These findings suggest the need for rational risk assessment with consideration of the diversity of patients with NMIBC.

Entities:  

Keywords:  bladder cancer; low-grade urothelial carcinoma; risk classification; tumor size

Year:  2018        PMID: 29732157      PMCID: PMC5921295          DOI: 10.3892/mco.2018.1602

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  16 in total

1.  Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.

Authors:  K Kurth; U Tunn; R Ay; F H Schröder; M Pavone-Macaluso; F Debruyne; F ten Kate; M de Pauw; R Sylvester
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

2.  Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder.

Authors:  Malte Rieken; Evanguelos Xylinas; Luis Kluth; Joseph J Crivelli; James Chrystal; Talia Faison; Yair Lotan; Pierre I Karakiewicz; Sten Holmäng; Marek Babjuk; Harun Fajkovic; Christian Seitz; Tobias Klatte; Armin Pycha; Alexander Bachmann; Douglas S Scherr; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2013-08-27       Impact factor: 20.096

Review 3.  A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

Authors:  Maurizio Brausi; J Alfred Witjes; Donald Lamm; Raj Persad; Joan Palou; Marc Colombel; Roger Buckley; Mark Soloway; Hideyuki Akaza; Andreas Böhle
Journal:  J Urol       Date:  2011-10-19       Impact factor: 7.450

4.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Authors:  Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner
Journal:  Eur Urol       Date:  2016-06-17       Impact factor: 20.096

5.  A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.

Authors:  W Oosterlinck; K H Kurth; F Schröder; J Bultinck; B Hammond; R Sylvester
Journal:  J Urol       Date:  1993-04       Impact factor: 7.450

6.  Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.

Authors:  C Bouffioux; K H Kurth; A Bono; W Oosterlinck; C B Kruger; M De Pauw; R Sylvester
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

7.  Long-term Bladder and Upper Urinary Tract Follow-up Recurrence and Progression Rates of G1-2 Non-muscle-invasive Urothelial Carcinoma of the Bladder.

Authors:  Thomas Golabesk; Joan Palou; Oscar Rodriguez; Ruben Parada; Sergio Skrobot; Juan Antonio Peña; Humberto Villavicencio
Journal:  Urology       Date:  2016-10-17       Impact factor: 2.649

8.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

Review 9.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Authors:  Holger Moch; Antonio L Cubilla; Peter A Humphrey; Victor E Reuter; Thomas M Ulbright
Journal:  Eur Urol       Date:  2016-02-28       Impact factor: 20.096

10.  Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.

Authors:  D W Newling; M R Robinson; P H Smith; D Byar; R Lockwood; I Stevens; M De Pauw; R Sylvester
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.